SomnoMed Limited (SOMNF)

OTCMKTS · Delayed Price · Currency is USD
0.5149
+0.0524 (11.33%)
At close: Dec 31, 2025
Market Cap97.32M +20.0%
Revenue (ttm)79.04M +18.2%
Net Income-1.71M
EPS-0.01
Shares Outn/a
PE Ration/a
Forward PE33.78
Dividendn/a
Ex-Dividend Daten/a
Volume300
Average Volume7,383
Open0.5149
Previous Close0.4625
Day's Range0.5149 - 0.5149
52-Week Range0.3675 - 0.5149
Beta0.94
RSI54.80
Earnings DateFeb 26, 2026

About SomnoMed

SomnoMed Limited, together with its subsidiaries, produce and sells devices for the oral treatment of sleep related disorders in the Asia Pacific region, North America, and Europe. It provides SomnoDent Avant, as well as SomnoDent Classic, SomnoDent Flex, and SomnoDent Fusion are offered for the treatment of obstructive sleep apnea. The company also offers SomMorning Repositioner, a product designed to help return patient’s mandible back to its pre-treatment centric position; SomnoBrux splint, a custom fit, acrylic splint for patient’s upper te... [Read more]

Sector Healthcare
Founded 1987
Employees 300
Stock Exchange OTCMKTS
Ticker Symbol SOMNF

Financial Performance

In fiscal year 2025, SomnoMed's revenue was 111.49 million, an increase of 21.65% compared to the previous year's 91.65 million. Losses were -3.46 million, -71.77% less than in 2024.

Financial numbers in AUD Financial Statements

News

SomnoMed Ltd (SOMNF) Half Year 2026 Earnings Call Highlights: Record Revenue and Strategic ...

SomnoMed Ltd (SOMNF) Half Year 2026 Earnings Call Highlights: Record Revenue and Strategic Investments

8 days ago - GuruFocus

Half Year 2026 Somnomed Ltd Earnings Call Transcript

Half Year 2026 Somnomed Ltd Earnings Call Transcript

8 days ago - GuruFocus

SomnoMed Limited (SOMNF) Q2 2026 Earnings Call Transcript

SomnoMed Limited (SOMNF) Q2 2026 Earnings Call Transcript

4 weeks ago - Seeking Alpha